Novel and emerging therapies for B cell lymphoma
Abstract Lymphomas are a heterogeneous group of lymphoproliferative disorders, with unique clinical and biological characteristics that exhibit variable response to therapy. Advances in chemo-immunotherapy have improved outcomes in a number of lymphoma subtypes; however, the prognosis for many patie...
Egile Nagusiak: | Sabarish Ayyappan, Kami Maddocks |
---|---|
Formatua: | Artikulua |
Hizkuntza: | English |
Argitaratua: |
BMC
2019-07-01
|
Saila: | Journal of Hematology & Oncology |
Gaiak: | |
Sarrera elektronikoa: | http://link.springer.com/article/10.1186/s13045-019-0752-3 |
Antzeko izenburuak
-
Correction to: Novel and emerging therapies for B cell lymphoma
nork: Sabarish Ayyappan, et al.
Argitaratua: (2021-02-01) -
Chemotherapy resistant Burkitt lymphoma: Possible novel therapies including CAR‐T cell infusion
nork: Paulus A. F. Geerts, et al.
Argitaratua: (2023-06-01) -
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma
nork: Alvaro J. Alencar, et al.
Argitaratua: (2021-11-01) -
Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma
nork: Yifan Pang, et al.
Argitaratua: (2024-04-01) -
Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported Outcomes
nork: Mohty R, et al.
Argitaratua: (2023-04-01)